Lipoprotein Apheresis - 02/05/15
, Linda Hemphill, MD bRésumé |
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level–lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients with FH with hypercholesterolemia. LA reduces LDL-C levels by more than 60% in patients with FH and reduces CVD events. LA also reduces Lp(a) levels and CVD events. LA reduces inflammatory markers and blood viscosity.
Le texte complet de cet article est disponible en PDF.Keywords : Lipoprotein apheresis, Familial hypercholesterolemia, LDL-C, CVD, Atherosclerosis, Lp(a)
Plan
| Disclosures: Dr P.M. Moriarty, Research for Amgen, Kowa, Lilly, Novartis, Sanofi, Regeneron, Genzyme, Pfizer, Catabasis, Espirion, B. Braun, and Kaneka; Consultant for Regeneron, Duke Clinical research Institute, Lilly, Catabasis, B Braun, Kaneka, and Genzyme; Honoraria from Esperion. |
|
| Dr L. Hemphill, Research: Regeneron, Sanofi and ISIS. |
Vol 33 - N° 2
P. 197-208 - mai 2015 Retour au numéro
Article précédent
- New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk : A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia
- Bhavin B. Adhyaru, Terry A. Jacobson
- Dyslipidemia in Pregnancy
- Robert Wild, Elizabeth A. Weedin, Don Wilson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?